OHSU

Kris Weymann, M.S., R.N. Share This OHSU Content

weymann-kris

PhD student, OHSU School of Nursing

2008-present

Lives in: Portland, OR

Dissertation Committee: 

Lisa Wood, Ph.D., R.N.
Lillian Nail, Ph.D., R.N.
Daniel Marks, M.D., Ph.D.

 

 

Focus Areas: 

Cancer treatment related fatigue, neural signaling of fatigue behavior, inflammation, recovery, gerontology

Research Interests: 

Role of Orexin Signaling in Cytoxic Chemotherapy Related Fatigue

Association of Poststroke Fatigue Trajectories with Cytokine Polymorphisms

Funding Sources:

NINR - F3 (2012 - present)
John A. Hartford Center-Building Academic Geriatric Nursing Capacity (2009-2011)
T32 Symptom Management
Oncology Nursing Society Conference Scholarship
OHSU School of Nursing Dean's Award (20130)

Publications

Wood, L.J. & Weyman, K. (2013). Inflammation and neural signaling:etiologic mechanisms of the cancer treatment-related symptom cluster. Current Opinion in Supportive & Palliative Care. 7, PMID:23314015.

Professional Organizations:

Sigma Theta Tau, Beta Psi Chapter
American Stroke Association
Gerontological Society of America
International Brain Barriers Society

Conference Participation as an OHSU-SON student:

Podium presentation Oncology Nursing Society-2013

Poster presentation WIN-2013

Poster presentation and Presidential Poster Award Winner, Endocrinology-2013

Podium presentation OHSU Research Week-2013

Podium presentation OHSU Nursing Research Conference-2013

International Stroke Conference

Blood-Brain Barrier Consortium Meeting

Gerontological Society of America

Interests:

I have studied responses to injury in a variety of different organisms. The inflammatory response, needed for defense and healing, is of particular interest to me since excessive or prolonged inflammation is damaging. Cytotoxic chemotherapy is known to induce peripheral inflammation. In my research I have found that it also induces inflammatory signaling in the brain stem and in the hypothalamus, regions critical for signaling wakefulness and activity. I have found that cytotoxic chemotherapy suppresses hypothalamic orexin neuron signaling and this suppression is associated with lethargy/fatigue. Orexin agonists are in the final steps of FDA approval to treat narcolepsy, a disorder characterized by disrupted wakefulness and disrupted sleep. This therapy might be useful to treat persistent fatigue and disrupted sleep associated with cytotoxic chemotherapy, traumatic brain injury, or stroke. As a neuro nurse, my long term goal is to improve functional recovery from disorders affecting brain function. When I am not pursuing inflammation , brain function, and related symptoms, I enjoy yoga, bike commuting, running, gardening, and generating electricity with my solar panels..